ASND Live signals | Maximize Profits with Getagraph.com

BUY 3195 min ago

@ $144.01

Issued: 24 Apr 2024 @ 09:31

Return: -5.64%

Previous signal: Apr 22 - 13:18

Previous signal: Sell

Return: 0.54 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 14:45):

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD)...

Stats
Today's Volume	147 900
Average Volume	352 493
Market Cap	7.69B
EPS	$0 ( 2024-04-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.60
ATR14	$3.52 (2.46%)

Volume Correlation

Long: 0.20 (neutral)

Short: 0.57 (weak)

Signal:(52) Neutral

Ascendis Pharma A/S Correlation

10 Most Positive Correlations
LMPX	0.937
ATHN	0.927
ASRV	0.906
WABC	0.903
FLIC	0.9
JRJC	0.899
NFBK	0.896
ISTR	0.896
BCBP	0.894
USCB	0.892

10 Most Negative Correlations
BMEA	-0.955
TMTS	-0.938
CLXT	-0.936
INZY	-0.927
ALDX	-0.925
ATVI	-0.924
SMFL	-0.913
CREX	-0.901
COCO	-0.899
RIVE	-0.898

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ascendis Pharma A/S Correlation - Currency/Commodity

-0.23
( neutral )

-0.30
( neutral )

0.00
( neutral )

-0.22
( neutral )

0.14
( neutral )

0.26
( neutral )

Ascendis Pharma A/S Financials

Annual	2023
Revenue:	$266.72M
Gross Profit:	$222.32M (83.36 %)
EPS:	$-8.55

FY	2023
Revenue:	$266.72M
Gross Profit:	$222.32M (83.36 %)
EPS:	$-8.55

FY	2022
Revenue:	$51.17M
Gross Profit:	$39.04M (76.28 %)
EPS:	$-10.40

FY	2021
Revenue:	$7.78M
Gross Profit:	$4.26M (54.71 %)
EPS:	$-7.00

Financial Reports:

No articles found.

Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.